Trial Profile

Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Selumetinib (Primary) ; Capecitabine; Docetaxel; Irinotecan
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms M14AFS

01 Apr 2021 Status changed from recruiting to completed.
31 May 2020 recommended phase II dose determined at 20 mg afatinib QD continuously and 25 mg selumetinib BID 21 days on/7 days off for continuous dosing as per results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results (N=26), of part A dose escalation, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com